Asthma: Pathophysiology, Triggers, Diagnostic Approach, and Evidence-Based Management for Preventing Exacerbations

Asthma is a chronic inflammatory disease of the airways characterized by airway hyperresponsiveness and variable airflow obstruction. Clinically, it manifests as recurrent episodes of wheeze, breathlessness, chest tightness, and cough, often worse at night or early morning. The defining feature is not only bronchoconstriction but also persistent inflammation that primes the airways to narrow with minimal stimuli. Understanding the immunologic and physiologic mechanisms is central to effective treatment and to reducing exacerbation risk.

At the tissue level, asthma involves multiple interacting processes. Airway inflammation is driven by complex immune pathways, frequently including type 2 (T2) inflammation with eosinophils, Th2 cells, and related cytokines such as IL-4, IL-5, and IL-13. These mediators promote mucus hypersecretion, goblet cell metaplasia, and impaired mucociliary clearance. Another contributor is airway remodeling, which results from chronic injury and repair cycles, including subepithelial fibrosis, smooth muscle hypertrophy, and thickening of the basement membrane. These structural changes contribute to long-term decline in lung function and increased likelihood of persistent symptoms.

Airflow limitation is typically reversible but fluctuates. Bronchial smooth muscle contraction is mediated by neural reflexes, inflammatory mediators, and local bronchoconstrictor cascades. Airway hyperresponsiveness arises when the airway becomes more sensitive to triggers such as allergens, viral infections, cold air, smoke, and occupational exposures. The net effect is airflow narrowing that can resolve with treatment, though severe attacks may lead to respiratory failure.

Common triggers include aeroallergens (dust mites, pet dander, pollen), tobacco smoke, air pollution, and respiratory viruses like rhinovirus and influenza. Physical exertion, gastroesophageal reflux, and medications such as non-selective beta-blockers or aspirin in sensitive individuals can also precipitate symptoms. Environmental management—reducing allergen load, improving indoor air quality, and addressing smoking exposure—is therefore a key component of care.

Diagnosis relies on clinical history plus objective assessment of variable airflow obstruction. Spirometry is the primary tool, demonstrating obstruction with reduced FEV1 and an elevated FEV1/FVC ratio that improves after bronchodilator therapy. If spirometry is normal or inconclusive but suspicion remains, bronchoprovocation testing (e.g., methacholine) or serial peak expiratory flow measurements may show variability. Fractional exhaled nitric oxide (FeNO) and blood eosinophil counts can support identification of T2-high asthma phenotypes, which may predict responsiveness to specific biologic therapies. Differential diagnoses—such as COPD, vocal cord dysfunction, heart failure, and allergic rhinitis—must be considered when presentations are atypical.

Management is structured around controlling inflammation and preventing exacerbations while relieving acute symptoms. Inhaled corticosteroids (ICS) are the cornerstone of controller therapy because they reduce airway inflammation and decrease exacerbation frequency. For patients with persistent symptoms, stepwise therapy may add long-acting beta2-agonists (LABA) in combination with ICS, or consider alternative controller regimens depending on symptom severity and phenotype. Short-acting beta2-agonists (SABA) are used as rescue medication for acute relief, though reliance on frequent rescue use indicates inadequate control.

For patients with severe asthma not adequately controlled with optimized inhaled therapy, targeted treatments may be indicated. Biologic agents include anti-IgE therapy (for allergic asthma), anti-IL-5/IL-5R agents (for eosinophilic asthma), and anti-IL-4Rα (targeting IL-4 and IL-13) or other pathway-specific options, selected based on biomarkers and clinical characteristics. In selected cases, bronchial thermoplasty may be considered, though its role is narrower and requires specialist evaluation.

Education and inhaler technique are critical because inadequate delivery to the lower airways undermines medication efficacy. Written asthma action plans improve adherence by outlining how to adjust therapy during worsening symptoms and when to seek emergency care. Comorbidity management—treating allergic rhinitis, obesity, reflux, and sleep-disordered breathing—also improves control. Vaccination against influenza and pneumococcus reduces infection-driven exacerbations, and smoking cessation is strongly recommended.

Acute exacerbation management focuses on rapid bronchodilation and aggressive anti-inflammatory therapy. In moderate to severe attacks, systemic corticosteroids shorten recovery and reduce relapse risk. Supplemental oxygen and, when needed, noninvasive ventilation or intubation are used for respiratory failure. Monitoring includes assessment of work of breathing, oxygen saturation, and response to therapy.

Overall, asthma care integrates phenotyping, guideline-based stepwise therapy, trigger reduction, and continuous reassessment. By targeting both reversible airway constriction and underlying inflammation, clinicians can improve quality of life, preserve lung function, and prevent severe, life-threatening exacerbations.

Source: @azma_wani (via the provided social media post)